secwatch.observer — SEC 8-K summary
======================================

Issuer:     SpyGlass Pharma, Inc. (SGP)
CIK:        0001778922
Form:       8-K
Filed at:   2026-10-01T12:15:18+00:00
Accession:  0001778922-26-000049
Event type: m_and_a
Sentiment:  positive
Materiality: 0.82
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

SpyGlass Pharma acquires AVS from Santen for $13M to secure IOL supply
----------------------------------------------------------------------

- SpyGlass Pharma closed its acquisition of 100% of Advanced Vision Science (AVS) from Santen Holdings US on October 1, 2026, for a purchase price of $13,000,000 in cash.
- AVS was SpyGlass Pharma's intraocular lens supplier and will continue to manufacture IOLs under the Eternity brand for Santen, which gets exclusive rights to sell those products in Japan.
- At closing, AVS and Santen Pharmaceutical Co., Ltd. signed an Amended and Restated Supply and Distribution Agreement and cross licenses.
- AVS will continue licensing its glistening-free hydrophobic acrylic lens material to Bausch + Lomb for the enVista IOL line and manufacturing for other global IOL companies.
- SpyGlass said the deal secures scalable commercial IOL manufacturing for its Phase 3 BIM-IOL System and may add toric and extended depth-of-focus premium lenses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1778922/000177892226000049/0001778922-26-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1778922/000177892226000049/sgp-20261001.htm
  HTML page:      https://secwatch.observer/filing/0001778922-26-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer